{"componentChunkName":"component---node-modules-gatsby-theme-buzzing-src-gatsby-theme-blog-core-templates-post-query-js","path":"/zh-Hant/reddit/r/investing/comments/kv332t/eli_lilly_up_20_after_donanemab_shows_clinical/","result":{"data":{"site":{"siteMetadata":{"title":"国外股市热门","description":"用中文浏览国外股票社区里的热门讨论","social":[{"name":"Reddit Stocks","url":"https://www.reddit.com/r/stocks","external":true,"prefetch":null},{"name":"Reddit Investing","url":"https://www.reddit.com/r/investing","external":true,"prefetch":null},{"name":"Reddit Bogleheads","url":"https://www.reddit.com/r/Bogleheads/","external":true,"prefetch":null},{"name":"Buzzing","url":"https://www.buzzing.cc/","external":true,"prefetch":null}],"menuLinks":[{"name":"每周精选","url":"/issues","external":null,"prefetch":null}],"localize":[{"title":"Buzzing on Stocks","description":"See popular discussions in foreign stock communities in your native language","locale":"en","social":[{"name":"Reddit","url":"https://www.reddit.com/","external":true,"prefetch":null}],"menuLinks":[{"name":"Weekly Selection","url":"/en/issues","external":null,"prefetch":null}]},{"title":"國外股市熱門","description":"用中文瀏覽國外股票社區裡的熱門討論","locale":"zh-Hant","social":null,"menuLinks":[{"name":"每週精選","url":"/zh-Hant/issues","external":null,"prefetch":null}]},{"title":"米国株式市場人気の話し合います","description":"人気の米国株式市場の話し合いまを日本語で閲覧","locale":"ja","social":null,"menuLinks":[{"name":"每週精選","url":"/ja/issues","external":null,"prefetch":null}]}]}},"blogPost":{"__typename":"SocialMediaPost","id":"RedditPost-kv332t","excerpt":" * Eli Lilly (NYSE:LLY\n   [https://seekingalpha.com/symbol/LLY?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link])\n   gains 20% in premarket on promising results\n   [https://seekingalpha.com/pr/18145426-lillys-donanemab-slows-clinical-decline-of…","body":"<!-- SC_OFF --><div class=\"md\"><ul>\n<li>Eli Lilly (NYSE:<a href=\"https://seekingalpha.com/symbol/LLY?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">LLY</a>) gains 20% in premarket on <a href=\"https://seekingalpha.com/pr/18145426-lillys-donanemab-slows-clinical-decline-of-alzheimers-disease-in-positive-phase-2-trial?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">promising results</a> from <a href=\"https://clinicaltrials.gov/ct2/show/NCT03367403?cond=trailblazer&amp;draw=2&amp;rank=1&amp;source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">Phase 2 TRAILBLAZER-ALZ study</a>, evaluating donanemab, an antibody that targets a  modified form of beta amyloid called N3pG, for Alzheimer&#39;s disease  (AD). The study met the primary endpoint of change from baseline to 76  weeks in AD rating scale.</li>\n<li>Data  showed that donanemab slowed the decline in a composite measure of  cognition and daily function by 32%, compared to placebo.</li>\n<li>Safety profile was consistent with observations from Phase 1 data.</li>\n<li>Full  results of the TRAILBLAZER-ALZ study will be presented at a future  medical congress and submitted for publication in a peer-reviewed  clinical journal.</li>\n<li>Lilly plans to  discuss these results with regulators to assess next steps for  donanemab. In addition, TRAILBLAZER-EXT is an ongoing trial for those  who participated in TRAILBLAZER-ALZ.</li>\n<li>Safety, tolerability and efficacy of donanemab are also being evaluated in another <a href=\"https://clinicaltrials.gov/ct2/show/NCT04437511?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">Phase 2 study TRAILBLAZER-ALZ 2</a>.</li>\n<li>Progress on Alzheimer&#39;s treatments was one reason cited by BofA in picking Lilly as a <a href=\"https://seekingalpha.com/news/3649105-bofas-biopharma-picks-2021-set-to-build-new-launches-beatable-expectations?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">top name for 2021</a>.</li>\n</ul>\n\n<p><a href=\"https://seekingalpha.com/news/3650196-eli-lilly-up-20-after-donanemab-shows-clinical-benefit-in-mid-stage-alzheimers-study\">https://seekingalpha.com/news/3650196-eli-lilly-up-20-after-donanemab-shows-clinical-benefit-in-mid-stage-alzheimers-study</a></p>\n</div><!-- SC_ON -->","slug":"/reddit/r/investing/comments/kv332t/eli_lilly_up_20_after_donanemab_shows_clinical/","title":"Eli Lilly up 20% after donanemab shows clinical benefit in mid-stage Alzheimer's study","tags":["investing","reddit"],"date":"January 13, 2021","dateISO":"2021-01-13T00:11:37.000Z","datetime":"2021-01-13 00:11","image":null,"imageAlt":null,"socialImage":null,"fields":{"basePath":"/"},"thirdPartyId":"kv332t","provider":"Reddit","url":"https://www.reddit.com/r/investing/comments/kv332t/eli_lilly_up_20_after_donanemab_shows_clinical/","originalUrl":"https://www.reddit.com/r/investing/comments/kv332t/eli_lilly_up_20_after_donanemab_shows_clinical/","imageRemote":null,"video":null,"channel":"investing","channelUrl":"https://www.reddit.com/r/investing","author":"Omg_Keynes","authorUrl":"https://www.reddit.com/user/Omg_Keynes","authorImage":null,"authorSlug":"Omg_Keynes","score":35,"views":null,"sharedCount":null,"likeCount":null,"sharedContent":null,"parent":{"__typename":"RedditJson","localize":[{"title":"Eli Lilly legt um 20% zu, nachdem Donanemab klinischen Nutzen in Alzheimer-Studie im mittleren Stadium zeigt","the_new_excerpt":" * Eli Lilly (NYSE:LLY\n   [https://seekingalpha.com/symbol/LLY?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link])\n   gewinnt 20% im vorbörslichen Handel aufgrund vielversprechender Ergebnisse\n   [https://seekingalpha.com/pr/18145426-lillys-donanemab-slows-clinical-decline-of...","locale":"zh"},{"title":"Eli Lilly legt um 20% zu, nachdem Donanemab klinischen Nutzen in Alzheimer-Studie im mittleren Stadium zeigt","the_new_excerpt":" * Eli Lilly (NYSE:LLY\n   [https://seekingalpha.com/symbol/LLY?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link])\n   gewinnt 20% im vorbörslichen Handel aufgrund vielversprechender Ergebnisse\n   [https://seekingalpha.com/pr/18145426-lillys-donanemab-slows-clinical-decline-of...","locale":"zh-Hant"}]}},"previous":{"id":"RedditPost-l6c5tg","excerpt":"To the SEC retards in this sub: go fuck yourself. Why don’t you start\ninvestigating why companies can shut down trading so their hedge fund buddies\ndon’t lose money. But when people lose money it’s completely ok. Eat a dick.","slug":"/reddit/r/wallstreetbets/comments/l6c5tg/just_read_a_new_york_times_article_saying_the_sec/","title":"Just read a New York Times article saying the SEC is reviewing this sub and what is going on....🎮🎮🎮🎮🎮 (SEC PLS READ)","date":"January 27, 2021","__typename":"SocialMediaPost","parent":{"__typename":"RedditJson","localize":[{"title":"刚看了一篇纽约时报的文章，说证监会正在审查这个子，是怎么回事....🎮🎮🎮🎮（证监会PLS阅读）。","the_new_excerpt":"致本子里的证监会弱智：去死吧。你为什么不开始\n调查为什么公司可以关闭交易，以便他们的对冲基金的朋友们\n不要赔钱。但是，当人们输钱的时候，完全可以。吃个鸡巴吧","locale":"zh"},{"title":"剛看了一篇紐約時報的文章，說證監會正在審查這個子，是怎麼回事....🎮🎮🎮🎮（證監會PLS閱讀）。","the_new_excerpt":"致本子裏的證監會弱智：去死吧。你爲什麼不開始\n調查爲什麼公司可以關閉交易，以便他們的對沖基金的朋友們\n不要賠錢。但是，當人們輸錢的時候，完全可以。喫個雞巴吧","locale":"zh-Hant"}]}},"next":{"id":"RedditPost-l66f7o","excerpt":"","slug":"/reddit/r/wallstreetbets/comments/l66f7o/even_the_mooch_knows_were_coming_for_the_suits/","title":"Even the MOOCH knows we’re coming for the suits!!!","__typename":"SocialMediaPost","date":"January 27, 2021","parent":{"__typename":"RedditJson","localize":[{"title":"连MOOCH都知道我们是冲着西装来的！!","the_new_excerpt":null,"locale":"zh"},{"title":"連MOOCH都知道我們是衝着西裝來的！!","the_new_excerpt":null,"locale":"zh-Hant"}]}}},"pageContext":{"id":"RedditPost-kv332t","previousId":"RedditPost-l6c5tg","nextId":"RedditPost-l66f7o","maxWidth":1024,"locale":"zh-Hant","hrefLang":"zh-Hant","originalPath":"/reddit/r/investing/comments/kv332t/eli_lilly_up_20_after_donanemab_shows_clinical/","dateFormat":"YYYY-MM-DD"}},"staticQueryHashes":["1239077767","2506312863","2744905544","3493603132","3493603132","3513215887","386998304"]}